The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells

Journal of Biological Chemistry

Volumn 287, Issue 27, 2012, Pages 23171-23183

  Li, Xiufen ^a   Kuang, Jinqiu ^b   Shen, Yi ^a   Majer, Martin M ^b   Nelson, Chad C ^c   Parsawar, Krishna ^c   Heichman, Karen A ^d   Kuwada, Scott K ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Oregon State University Oregon Health Science University College of Pharmacy   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELLS; CELL LINES; CHROMATIN IMMUNOPRECIPITATION; ISOFORMS; KINASE ACTIVITY; MACRO DOMAINS; OVER-EXPRESSION; TUMORIGENICITY;

CELL CULTURE; CELL PROLIFERATION; TRANSCRIPTION; TRANSCRIPTION FACTORS;

CELLS;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H2A; HISTONE H2A1.2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL FRACTIONATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; FEMALE; GENE DUPLICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BREAST NEOPLASMS; CACO-2 CELLS; CELL DIVISION; CELL NUCLEUS; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONES; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTOR, ERBB-2;

EID: 84863307537     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.379412     Document Type: Article

References (43)

1. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K., and Spaventi, R. (1997) The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112, 1103-1113 (Pubitemid 27157520)
2. Kapitanovic, S., Radosevic, S., Slade, N., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., Spaventi, S., Pavelic, K., and Spaventi, R. (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J. Cancer Res. Clin. Oncol. 126, 205-211 (Pubitemid 30183023)
3. Kapitanovic, S., Spaventi, R., Poljak, L., Kapitanovic, M., Pavelic, Z. P., Gluckman, J. L., Spaventi, S., and Pavelic, K. (1994) High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect. Prev. 18, 97-101 (Pubitemid 2077553)
4. Ross, J. S., and McKenna, B. J. (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19, 554-568 (Pubitemid 32619394)
5. Koka, V., Potti, A., Koch, M., Fraiman, G., Mehdi, S., and Levitt, R. (2002) Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res. 22, 1593-1597 (Pubitemid 34839169)
6. Pegram, M. D., Pauletti, G., and Slamon, D. J. (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res. Treat. 52, 65-77 (Pubitemid 29056086)
7. Nathanson, D. R., Shia, J., Chen, B., D'Alessio, M., Zeng, Z. S., Nash, G. M., Gerald, W., Barany, F., and Paty, P. B. (2003) HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105, 796-802 (Pubitemid 36706103)
8. Novotný, J., Petruzelka, L., Vedralová, J., Kleibl, Z., Matous, B., and Juda, L. (2001) Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma 48, 188-191 (Pubitemid 32678683)
9. Saxby, A. J., Nielsen, A., Scarlett, C. J., Clarkson, A., Morey, A., Gill, A., and Smith, R. C. (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RTPCR, and FISH with aneuploidy and survival. Am. J. Surg. Pathol. 29, 1125-1134 (Pubitemid 41232983)
10. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., and Marks, P. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50, 4087-4091 (Pubitemid 20225635)
11. Kono, K., Takahashi, A., Amemiya, H., Ichihara, F., Sugai, H., Iizuka, H., Fujii, H., and Matsumoto, Y. (2002) Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer. Int. J. Cancer 98, 216-220 (Pubitemid 34150805)
12. Sadasivan, R., Morgan, R., Jennings, S., Austenfeld, M., Van Veldhuizen, P., Stephens, R., and Noble, M. (1993) Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J. Urol. 150, 126-131
13. Tiwari, R. K., Borgen, P. I., Wong, G. Y., Cordon-Cardo, C., and Osborne, M. P. (1992) HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 12, 419-425
14. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (Pubitemid 27151960)
15. Liccardi, G., Hartley, J. A., and Hochhauser, D. (2011) EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 71, 1103-1114
16. Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Kehlbach, R., and Rodemann, H. P. (2010) Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654. FEBS Lett. 584, 3878-3884
17. Hsu, S. C., Miller, S. A., Wang, Y., and Hung, M. C. (2009) Nuclear EGFR is required for cisplatin resistance and DNA repair. Am. J. Transl. Res. 1, 249-258
18. Li, C., Iida, M., Dunn, E. F., Ghia, A. J., and Wheeler, D. L. (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801-3813
19. Farin, K., Di Segni, A., Mor, A., and Pinkas-Kramarski, R. (2009) Structure-function analysis of nucleolin and ErbB receptors interactions. PLoS One 4, e6128
20. Lo, H. W., Ali-Seyed, M., Wu, Y., Bartholomeusz, G., Hsu, S. C., and Hung, M. C. (2006) Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1. J. Cell. Biochem. 98, 1570-1583 (Pubitemid 44141861)
21. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3, 802-808 (Pubitemid 32842685)
22. Marti, U., Ruchti, C., Kämpf, J., Thomas, G. A., Williams, E. D., Peter, H. J., Gerber, H., and Bürgi, U. (2001) Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid 11, 137-145 (Pubitemid 32221036)
23. Xie, Y., and Hung, M. C. (1994) Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem. Biophys. Res. Commun. 203, 1589-1598
24. Béguelin, W., Díaz Flaqué, M. C., Proietti, C. J., Cayrol, F., Rivas, M. A., Tkach, M., Rosemblit, C., Tocci, J. M., Charreau, E. H., Schillaci, R., and Elizalde, P. V. (2010) Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol. Cell. Biol. 30, 5456-5472
25. Kuwada, S. K., Scaife, C. L., Kuang, J., Li, X., Wong, R. F., Florell, S. R., Coffey, R. J., Jr., and Gray, P. D. (2004) Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int. J. Cancer 109, 291-301 (Pubitemid 38240934)
26. Sporn, J. C., Kustatscher, G., Hothorn, T., Collado, M., Serrano, M., Muley, T., Schnabel, P., and Ladurner, A. G. (2009) Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 28, 3423-3428
27. Ladurner, A. G. (2003) Inactivating chromosomes: a macro domain that minimizes transcription. Mol. Cell 12, 1-3
28. Gamble, M. J., Frizzell, K. M., Yang, C., Krishnakumar, R., and Kraus, W. L. (2010) The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev. 24, 21-32
29. Pehrson, J. R., and Fried, V. A. (1992) MacroH2A, a core histone containing a large nonhistone region. Science 257, 1398-1400
30. Gamble, M. J., and Kraus, W. L. (2010) Multiple facets of the unique histone variant macroH2A: from genomics to cell biology. Cell Cycle 9, 2568-2574
31. Kustatscher, G., Hothorn, M., Pugieux, C., Scheffzek, K., and Ladurner, A. G. (2005) Splicing regulates NAD metabolite binding to histone macroH2A. Nat. Struct. Mol. Biol. 12, 624-625 (Pubitemid 40980814)
32. Ogawa, Y., Ono, T., Wakata, Y., Okawa, K., Tagami, H., and Shibahara, K. I. (2005) Histone variant macroH2A1.2 is mono-ubiquitinated at its histone domain. Biochem. Biophys. Res. Commun. 336, 204-209 (Pubitemid 41253422)
33. Pehrson, J. R., Costanzi, C., and Dharia, C. (1997) Developmental and tissue expression patterns of histone macroH2A1 subtypes. J. Cell. Biochem. 65, 107-113 (Pubitemid 27188073)
34. Wang, S. C., Lien, H. C., Xia, W., Chen, I. F., Lo, H. W., Wang, Z., Ali-Seyed, M., Lee, D. F., Bartholomeusz, G., Ou-Yang, F., Giri, D. K., and Hung, M. C. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6, 251-261 (Pubitemid 39222038)
35. Xing, X., Wang, S. C., Xia, W., Zou, Y., Shao, R., Kwong, K. Y., Yu, Z., Zhang, S., Miller, S., Huang, L., and Hung, M. C. (2000) The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med. 6, 189-195 (Pubitemid 30082364)
36. Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S., Nobel, A. B., van't Veer, L. J., and Perou, C. M. (2006) Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560-569 (Pubitemid 44200649)
37. Half, E., Broaddus, R., Danenberg, K. D., Danenberg, P. V., Ayers, G. D., and Sinicrope, F. A. (2004) HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int. J. Cancer 108, 540-548 (Pubitemid 38036654)
38. Richardson, A. L., Wang, Z. C., De Nicolo, A., Lu, X., Brown, M., Miron, A., Liao, X., Iglehart, J. D., Livingston, D. M., and Ganesan, S. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (Pubitemid 43202662)
39. Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., Demeter, J., Perou, C. M., Lønning, P. E., Brown, P. O., Børresen-Dale, A. L., and Botstein, D. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100, 8418-8423 (Pubitemid 36842560)
40. Chung, C. H., Bernard, P. S., and Perou, C. M. (2002) Molecular portraits and the family tree of cancer. Nat. Genet. 32, (suppl.) 533-540 (Pubitemid 35435158)
41. Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., Smith, D., Hartmann, L., Fishman, D., Berchuck, A., Schmandt, R., Whitaker, R., Gershenson, D. M., Mills, G. B., and Bast, R. C., Jr. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291-3300 (Pubitemid 38685433)
42. Hendrix, N. D., Wu, R., Kuick, R., Schwartz, D. R., Fearon, E. R., and Cho, K. R. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 66, 1354-1362 (Pubitemid 43259914)
43. Graudens, E., Boulanger, V., Mollard, C., Mariage-Samson, R., Barlet, X., Grémy, G., Couillault, C., Lajémi, M., Piatier-Tonneau, D., Zaborski, P., Eveno, E., Auffray, C., and Imbeaud, S. (2006) Deciphering cellular states of innate tumor drug responses. Genome Biol. 7, R19